Digital Selection and Evaluation of State Negotiates Drugs of New GLP-1RA Semaglutide Injection

OBJECTIVE To actively promote the state negotiates drugs of new glucagon-like peptide-1 receptor agonist (GLP-1RA) weekly preparation of semaglutide injection clinical admission work. METHODS The effectiveness, pharmaceutical properties, safety, economy and other properties of semaglutide injection were digitally evaluated by three steps of optimization of quantitative evaluation system, collection of evidence and comprehensive analysis and decision. RESULTS After evaluation, the half-life of semaglutide injection was prolonged to 7 d by structural optimization, which was the longest in GLP-1RA weekly preparations. The amino acid sequence homology with human GLP-1 was the highest in GLP-1RA weekly preparations, and the incidence of allergic reaction was the lowest. Because of its unique cardiovascular benefits, it was recommended in several guidelines such as 《American Standards of Medical Care in Diabetes(2022)》 and 《Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China(2020)》 for patients with atherosclerotic cardiovascular disease as an initial treatment and as a primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. After the evaluation system was optimized, the efficacy score of semaglutide injection was 25 points, the pharmaceutical property score was 17.4 points, the safety score was 7.6 points, the economic score was 17 points, and the other attributes score was 11.3 points, total score was 78.3. The selection recommendation level was “recommendation”. CONCLUSION The first three core attributes of semaglutide injection were good. The price was in the mid-range of GLP-1RA weekly preparations after be negotiated by Medicare, greatly increasing its accessibility to patients with type 2 diabetes mellitus. The digital selection and evaluation of semaglutide injection provided decision support for the drug’s admission implemented.